Werewolf Therapeutics Inc Cash Flow Conversion Efficiency
Werewolf Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of 0.407x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.63 Million) by net assets ($16.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Werewolf Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2025. This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Werewolf Therapeutics Inc share price for real-time trading data and today's change.
Werewolf Therapeutics Inc Cash Flow Conversion Ratio Explained
Werewolf Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency. Also see HOWL stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mentice AB
ST:MNTC
|
0.067x |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
-0.002x |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
0.030x |
|
Aeye Inc
NASDAQ:LIDR
|
-0.107x |
|
Ramaco Resources Inc.
NASDAQ:METCB
|
-0.079x |
|
seha corporation
KO:027970
|
0.017x |
|
Kodiak Copper Corp
V:KDK
|
-0.019x |
|
Lion Chemtech Co. Ltd
KQ:171120
|
0.012x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2025. Review HOWL free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.80 Million | $-60.29 Million | -2.431x | -217.48% |
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more